Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 170 clinical trials
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (FIGHT-209)

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblatoma (GBM) or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 3 cohorts, Cohorts A, B, and C, and will enroll approximately 82, 82, and 25 participants into each cohort, respectively. …

karnofsky performance status
temozolomide
ccnu
FGFR1
EGFR
  • 3 views
  • 22 Oct, 2022
  • 27 locations
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

  • 33 views
  • 25 Oct, 2022
  • 20 locations
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at

brain tumor
recurrent malignant glioma
malignant glioma
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Single-center, Single-arm, Open-label Phase 1 Clinical Trial to Assess the Safety and Tolerability of YYB-103, IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell (CAR-T) in Treating Patients With Refractory or Recurrent Malignant Glioma

This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the

  • 0 views
  • 14 Oct, 2022
  • 1 location
  • 0 views
  • 23 Oct, 2022
  • 1 location
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the …

brain tumor
karnofsky performance status
cancer
recurrent glioblastoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) (PNOC020)

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT unmethylated). Funding Source - FDA OOPD

  • 0 views
  • 07 Oct, 2022
  • 1 location
Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

The investigators will develop the concept of a sex-specific therapeutic intervention for gliomas that is based upon dietary carbohydrate restriction. The investigators will integrate

  • 7 views
  • 04 Oct, 2022
  • 1 location
Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

Microdialysis permits sampling of molecules from the extracellular fluid, and has been utilized for studies of pharmacokinetics, and recovery of biomarkers. Gliomas remain incurable--in part due

  • 0 views
  • 04 Oct, 2022
  • 1 location
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, …

  • 0 views
  • 04 Oct, 2022
  • 6 locations